ArticleDiscover oncology2025
Investigating the expression of hsa_circ_0036722/hsa-miR-503-5p/PDCD4 axis in esophageal cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exosomal miR-373-3p Derived from Docetaxel-Resistant Lung Cancer Cells Targets PDCD4 to Promote Proliferation and Inhibit Apoptosis in Lung Cancer Cells.Biomedicines · 2026Article
- Long non-coding RNA LINC00092 inhibits esophageal squamous cell carcinoma progression by promoting ferroptosis through the MAZ/NFE2L2 axis.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEsophageal cancer (EC) is the ninth most common cancer globally. Circular RNAs (circRNAs), including hsa_circ_0036722, are important in various cancers, but their specific role in EC remains unclear. Therefore, this study investigates the roles of hsa_circ_0036722 in EC.
methodsWe analyzed circRNAs sequencing from Gene Expression Omnibus (GEO). On the other hand, analyzed miRNAs and mRNAs sequencing related to EC from The Cancer Genome Atlas (TCGA). Then, the hsa_circ_0036722/hsa-mir-503-5p/PDCD4 axis was identified using online tools for detecting circRNA-associated miRNAs and target mRNAs. Gene expression levels in 20 EC tissue pairs were assessed using RT-qPCR, while PDCD4 protein expression was evaluated by Western blot. A receiver operating characteristic (ROC) analysis was performed to evaluate their diagnostic potential.
resultsRT-qPCR results demonstrated decreased expression of hsa_circ_0036722 and PDCD4, alongside increased hsa-miR-503-5p expression in EC tissues. A reduction in PDCD4 protein expression was also noted. Correlations showed that hsa_circ_0036722 and PDCD4 expressions were positively correlated, while hsa_circ_0036722 and hsa-miR-503-5p were negatively correlated. In addition, a significant negative correlation was observed between hsa-miR-503-5p and PDCD4 expression. Elevated levels of hsa-miR-503-5p were detected in early stages of EC. The ROC curve reflected a significant area under the curve for the axis genes.
conclusionThis study identified a novel regulatory axis, hsa_circ_0036722/hsa-mir-503-5p/PDCD4, for regulating EC, which may be a potential target for treating patients with this cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.